CN104684552B - 组合及其用途 - Google Patents
组合及其用途 Download PDFInfo
- Publication number
- CN104684552B CN104684552B CN201380050577.7A CN201380050577A CN104684552B CN 104684552 B CN104684552 B CN 104684552B CN 201380050577 A CN201380050577 A CN 201380050577A CN 104684552 B CN104684552 B CN 104684552B
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- antibody
- melphalan
- specific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705172P | 2012-09-25 | 2012-09-25 | |
| US61/705,172 | 2012-09-25 | ||
| US201361774595P | 2013-03-08 | 2013-03-08 | |
| US61/774,595 | 2013-03-08 | ||
| PCT/EP2013/069858 WO2014048921A1 (en) | 2012-09-25 | 2013-09-24 | Combinations and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104684552A CN104684552A (zh) | 2015-06-03 |
| CN104684552B true CN104684552B (zh) | 2018-08-07 |
Family
ID=49237209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380050577.7A Active CN104684552B (zh) | 2012-09-25 | 2013-09-24 | 组合及其用途 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9579378B2 (enExample) |
| EP (1) | EP2900232B1 (enExample) |
| JP (1) | JP6426093B2 (enExample) |
| KR (1) | KR102171669B1 (enExample) |
| CN (1) | CN104684552B (enExample) |
| AU (1) | AU2013322806C1 (enExample) |
| BR (1) | BR112015006731A2 (enExample) |
| CA (1) | CA2885792C (enExample) |
| DK (1) | DK2900232T3 (enExample) |
| ES (1) | ES2658953T3 (enExample) |
| HR (1) | HRP20171964T1 (enExample) |
| HU (1) | HUE036518T2 (enExample) |
| IL (1) | IL237926B (enExample) |
| LT (1) | LT2900232T (enExample) |
| MX (1) | MX368288B (enExample) |
| NZ (1) | NZ706147A (enExample) |
| PL (1) | PL2900232T3 (enExample) |
| PT (1) | PT2900232T (enExample) |
| RU (1) | RU2650618C2 (enExample) |
| SG (1) | SG11201502163QA (enExample) |
| WO (1) | WO2014048921A1 (enExample) |
| ZA (1) | ZA201501980B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035250T2 (hu) | 2005-10-12 | 2018-05-02 | Morphosys Ag | Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| SG11201701867SA (en) | 2014-09-09 | 2017-04-27 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| WO2016089960A1 (en) | 2014-12-04 | 2016-06-09 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| MA42136A (fr) | 2015-05-20 | 2018-03-28 | Janssen Biotech Inc | Anticorps anti-cd38 pour le traitement de l'amyloïdose à chaînes légères et d'autres tumeurs malignes hématologiques positives à cd38 |
| US10668149B2 (en) | 2015-06-22 | 2020-06-02 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| PH12018500950B1 (en) | 2015-11-03 | 2023-09-20 | Janssen Biotech Inc | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| EP3423498A1 (en) * | 2016-03-04 | 2019-01-09 | MorphoSys AG | Clinical assessment of m-protein response in multiple myeloma |
| EP3421494A1 (en) * | 2017-06-29 | 2019-01-02 | Sanofi | Use of isatuximab in combination with an anti-pd-1 antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| SG11202107319PA (en) * | 2019-03-15 | 2021-08-30 | Morphosys Ag | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007042309A2 (en) * | 2005-10-12 | 2007-04-19 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| WO2010061357A1 (en) * | 2008-11-28 | 2010-06-03 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan |
| WO2010061360A1 (en) * | 2008-11-28 | 2010-06-03 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide |
| WO2011154453A1 (en) * | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
| WO2012041800A1 (en) * | 2010-09-27 | 2012-04-05 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| CA2329940A1 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| JP2005512044A (ja) | 2001-12-03 | 2005-04-28 | アブジェニックス・インコーポレーテッド | 結合特性に基づく抗体分類 |
| WO2006125640A2 (en) | 2005-05-24 | 2006-11-30 | Morphosys Ag | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| JP2008504013A (ja) | 2004-02-06 | 2008-02-14 | モルフォシス・アクチェンゲゼルシャフト | 抗ｃｄ３８ヒト抗体及びその用途 |
| EA037929B1 (ru) | 2005-03-23 | 2021-06-08 | Генмаб А/С | Антитела к cd38 человека и их применение |
| ME03503B (me) | 2006-09-26 | 2020-04-20 | Genmab As | Anti-cd38 plus kortkosteroidni plus ne-kortikosteroidni hemoterapeutik za tretiranje tumora |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| EP2726477A4 (en) | 2011-06-29 | 2015-08-26 | Harvard College | SMALL MOLECULAR CD38 HEMMER AND USE METHOD THEREFOR |
| ES2808565T3 (es) | 2013-03-13 | 2021-03-01 | Sanofi Sa | Composiciones que comprenden anticuerpos anti-CD38 y carfilzomib |
| CA2909952C (en) | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
-
2013
- 2013-09-24 AU AU2013322806A patent/AU2013322806C1/en active Active
- 2013-09-24 RU RU2015110981A patent/RU2650618C2/ru active
- 2013-09-24 DK DK13766523.8T patent/DK2900232T3/en active
- 2013-09-24 SG SG11201502163QA patent/SG11201502163QA/en unknown
- 2013-09-24 PT PT137665238T patent/PT2900232T/pt unknown
- 2013-09-24 ES ES13766523.8T patent/ES2658953T3/es active Active
- 2013-09-24 EP EP13766523.8A patent/EP2900232B1/en active Active
- 2013-09-24 PL PL13766523T patent/PL2900232T3/pl unknown
- 2013-09-24 CN CN201380050577.7A patent/CN104684552B/zh active Active
- 2013-09-24 LT LTEP13766523.8T patent/LT2900232T/lt unknown
- 2013-09-24 JP JP2015532454A patent/JP6426093B2/ja active Active
- 2013-09-24 MX MX2015003589A patent/MX368288B/es active IP Right Grant
- 2013-09-24 WO PCT/EP2013/069858 patent/WO2014048921A1/en not_active Ceased
- 2013-09-24 BR BR112015006731A patent/BR112015006731A2/pt not_active Application Discontinuation
- 2013-09-24 KR KR1020157007554A patent/KR102171669B1/ko active Active
- 2013-09-24 US US14/430,801 patent/US9579378B2/en active Active
- 2013-09-24 HR HRP20171964TT patent/HRP20171964T1/hr unknown
- 2013-09-24 HU HUE13766523A patent/HUE036518T2/hu unknown
- 2013-09-24 NZ NZ706147A patent/NZ706147A/en unknown
- 2013-09-24 CA CA2885792A patent/CA2885792C/en active Active
-
2015
- 2015-03-23 ZA ZA2015/01980A patent/ZA201501980B/en unknown
- 2015-03-24 IL IL237926A patent/IL237926B/en active IP Right Grant
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007042309A2 (en) * | 2005-10-12 | 2007-04-19 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| WO2010061357A1 (en) * | 2008-11-28 | 2010-06-03 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan |
| WO2010061360A1 (en) * | 2008-11-28 | 2010-06-03 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide |
| WO2011154453A1 (en) * | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
| WO2012041800A1 (en) * | 2010-09-27 | 2012-04-05 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
Also Published As
| Publication number | Publication date |
|---|---|
| IL237926B (en) | 2020-04-30 |
| NZ706147A (en) | 2018-10-26 |
| EP2900232A1 (en) | 2015-08-05 |
| AU2013322806B2 (en) | 2017-11-30 |
| CN104684552A (zh) | 2015-06-03 |
| IL237926A0 (en) | 2015-05-31 |
| KR102171669B1 (ko) | 2020-10-30 |
| BR112015006731A2 (pt) | 2017-07-04 |
| CA2885792C (en) | 2021-09-28 |
| LT2900232T (lt) | 2018-02-26 |
| AU2013322806C1 (en) | 2018-03-08 |
| DK2900232T3 (en) | 2018-02-05 |
| PL2900232T3 (pl) | 2018-05-30 |
| MX368288B (es) | 2019-09-27 |
| PT2900232T (pt) | 2018-02-09 |
| SG11201502163QA (en) | 2015-04-29 |
| US20150238603A1 (en) | 2015-08-27 |
| US9579378B2 (en) | 2017-02-28 |
| ZA201501980B (en) | 2017-11-29 |
| HUE036518T2 (hu) | 2018-07-30 |
| WO2014048921A1 (en) | 2014-04-03 |
| MX2015003589A (es) | 2015-08-12 |
| JP2015530399A (ja) | 2015-10-15 |
| ES2658953T3 (es) | 2018-03-13 |
| CA2885792A1 (en) | 2014-04-03 |
| RU2015110981A (ru) | 2016-11-20 |
| HRP20171964T1 (hr) | 2018-02-23 |
| RU2650618C2 (ru) | 2018-04-16 |
| KR20150090030A (ko) | 2015-08-05 |
| JP6426093B2 (ja) | 2018-11-28 |
| EP2900232B1 (en) | 2017-11-15 |
| AU2013322806A1 (en) | 2015-04-09 |
| HK1210949A1 (en) | 2016-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104684552B (zh) | 组合及其用途 | |
| US11591406B2 (en) | Treatment for multiple myeloma (MM) | |
| WO2025002280A1 (en) | Combination therapies for the treatment of cancer | |
| CN113993543B (zh) | 使用抗cd38抗体的组合疗法 | |
| WO2024041652A1 (en) | Methods of cancer treatment | |
| HK1210949B (zh) | 组合及其用途 | |
| AU2023278019A1 (en) | Combination therapies for the treatment of non-small cell lung cancer | |
| TW202502813A (zh) | 包含偶聯物的藥物組合的治療方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1210949 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: Praneger, Germany Patentee after: Morphosys AG Address before: Martins Reed Germany Patentee before: Morphosys AG |
|
| CP02 | Change in the address of a patent holder |